Two major advances are transforming how eye doctors treat serious vision conditions, offering patients fewer clinic visits and children a chance to slow the progression of nearsightedness before it leads to lifelong complications. The FDA has approved extended dosing intervals for EYLEA HD (aflibercept), allowing some patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) to receive treatment as infrequently as every 20 weeks, or roughly 2 to 3 times per year. Meanwhile, Stellest lenses, a new eyeglass technology, are showing remarkable results in slowing myopia progression in children by an average of 67 percent compared to standard lenses .

What Does Extended Dosing Mean for Patients With Retinal Disease?

For millions of Americans living with wAMD and DME, frequent eye injections have been a necessary burden of treatment. wAMD affects approximately 1.4 million Americans and occurs when abnormal blood vessels grow and leak fluid under the macula, the part of the eye responsible for sharp central vision. DME, which can develop at any stage of diabetic retinopathy, affects roughly 1.5 million adults in the United States .

The new EYLEA HD approval is based on 96-week data from two pivotal trials called PULSAR (for wAMD) and PHOTON (for DME). Among patients who completed two years of treatment, the results were striking: 47 percent of wAMD patients and 44 percent of DME patients achieved dosing intervals of every 20 weeks or longer, while maintaining their visual and anatomic improvements .

"The potential for needing only 2 or 3 EYLEA HD injections a year to manage certain retinal diseases is an exciting advance that could benefit my patients who have been successfully treated for a year, particularly as safety, durability and flexibility continue to be driving forces behind treatment decisions," said Michael A. Klufas, M.D., Wills Eye Hospital Retina Service.

Michael A. Klufas, M.D., Wills Eye Hospital Retina Service

This flexibility matters enormously for patient quality of life. Rather than committing to monthly or every-other-month injections indefinitely, patients who respond well to treatment can space out their visits significantly. The approval also allows doctors to individualize dosing, meaning some patients may still need treatment every 4 weeks if their disease requires it, while others can extend to 20 weeks .

How Can Parents Slow Their Child's Worsening Nearsightedness?

Childhood myopia is accelerating at an alarming rate, with many children experiencing stronger prescriptions each year. This progression is more than a cosmetic concern. As the eye elongates during childhood, it increases the risk of serious eye diseases later in life, including retinal detachments, glaucoma, early cataracts, and myopic macular degeneration .

Stellest lenses offer a scientifically validated solution. These specialty eyeglass lenses look and feel like ordinary glasses but contain advanced optical technology called H.A.L.T. (Highly Aspherical Lenslet Target). The lenses feature hundreds of tiny, precisely shaped lenslets surrounding a clear central zone. These lenslets create a subtle treatment signal that helps control how the eye grows, while the center of the lens provides sharp, clear vision. Children don't see or feel the lenslets during daily activities .

In long-term clinical trials, children who wore Stellest lenses as recommended experienced an average 67 percent reduction in myopia progression compared to those wearing standard single-vision lenses. This means fewer prescription changes and healthier eye development over time .

Steps to Getting Started With Myopia Management for Your Child

• Schedule a Comprehensive Eye Exam: Eye doctors use advanced testing, including axial length measurements, to determine each child's level of risk and recommend personalized treatment options based on their specific situation.
• Evaluate Your Child's Risk Factors: Children with a family history of nearsightedness, those who spend significant time indoors on screens or reading, or those experiencing yearly prescription increases are ideal candidates for myopia-control interventions.
• Explore Multiple Treatment Options: Beyond Stellest lenses, doctors may discuss orthokeratology (overnight contact lenses), soft myopia-control contact lenses, or low-dose atropine therapy, depending on your child's age, lifestyle, and prescription needs.
• Commit to Regular Follow-Up Care: A myopia management consultation includes evaluation of vision and eye health, measurement of eye length to assess progression risk, review of lifestyle factors like outdoor time and screen habits, and creation of a personalized follow-up plan.

The earlier intervention begins, the better the outcomes tend to be. By slowing prescription changes during childhood, Stellest lenses can help reduce lifetime risk of serious eye diseases, improve long-term visual stability, and lower the likelihood of developing high myopia .

Why Should You Know About These Advances Now?

Both of these developments represent significant shifts in how eye doctors approach treatment. For adults with retinal disease, fewer injections mean less time away from work or family, reduced stress from frequent medical appointments, and the same level of disease control. For children, early intervention with Stellest lenses or other myopia-control methods can prevent decades of vision complications .

If you or a family member has been diagnosed with wAMD, DME, or childhood myopia, these advances are worth discussing with your eye care provider. The goal is no longer just managing vision loss but actively slowing disease progression and protecting long-term eye health.